Skip to main content
Skip to main content
AVTR logo

Avantor, Inc. (AVTR)

$10.20 $-0.17 (-1.63%) |Fair · 48
Signals are mixed — the Council read leans BUY (58/100) while the AI fundamental score is 48/100 (grade C); the two lenses disagree, so weigh the breakdown below. Strongest single signal: Seth Klarman bullish.
MCap: $6.96B| P/E Ratio: 9.2| Vol: 6.18M| Target: $10.89 (+6.8%)| 52-wk range: $7.26 – $15.93
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Avantor, Inc. (AVTR) trades at $10.20 with AI Score 48/100 (Grade C). Avantor, Inc. provides mission-critical products and services to the biopharma, healthcare, education, government, advanced technologies, and applied materials industries. Market cap: $6.96B, Sector: Healthcare.

Price live · AI analysis from May 4, 2026
Avantor, Inc. provides mission-critical products and services to the biopharma, healthcare, education, government, advanced technologies, and applied materials industries. The company offers a range of materials, consumables, equipment, instrumentation, and specialty procurement services.

AVTR stock analysis for 2026: Analysts have set a consensus price target of $10.89 for Avantor, Inc., suggesting 6.8% upside from the current price of $10.20. The AI MoonshotScore is 48/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
BUY 58/100 · B

AVTR: 4/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Bullish
Jim Simons
Bullish
Izzy Englander
Neutral
Seth Klarman
Bullish
Moon AI
Neutral
Council Score · 8 perspectives · See tabs for details →

Avantor, Inc. (AVTR) Healthcare & Pipeline Overview

CEOEmmanuel Ligner
Employees13500
HeadquartersRadnor, PA, US
IPO Year2019

Avantor, Inc. delivers essential products and services to diverse sectors including biopharma, healthcare, and advanced technologies. With a broad portfolio of materials, equipment, and specialty services, Avantor supports critical research and production processes across the Americas, Europe, Asia, and Africa, maintaining a significant presence in the medical instruments and supplies market.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 4, 2026

What Is the Investment Thesis for AVTR?

Avantor, Inc. presents a compelling investment case based on its diversified revenue streams and exposure to high-growth sectors like biopharma and advanced technologies. The company’s comprehensive product and service portfolio, ranging from materials and consumables to equipment and specialty services, provides resilience against economic cycles. While the company currently has a negative profit margin of -8.4%, growth catalysts include expanding its service offerings and penetrating emerging markets. The company's beta of 1.00 indicates market correlation. Key value drivers include strategic acquisitions, operational efficiencies, and increasing demand for biopharmaceutical materials. However, investors should be aware of risks such as intense competition and potential fluctuations in demand from key customer segments.

Based on FMP financials and quantitative analysis

AVTR Key Highlights

  • Avantor serves a diverse range of industries including biopharma, healthcare, education and government, advanced technologies, and applied materials.
  • The company offers a broad portfolio of materials and consumables, equipment and instrumentation, and services and specialty procurements.
  • Avantor has a global presence, serving customers in the Americas, Europe, Asia, the Middle East, and Africa.
  • The company's gross margin is 32.1%.
  • Avantor employs approximately 13,500 people.

Who Are AVTR's Competitors?

AVTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
MOH Molina Healthcare, Inc. $232.90 +2.28% $12.13B 81
MASI Masimo Corporation $179.95 +0.00% $9.42B 55
BAX Baxter International Inc. $23.09 +2.28% $11.93B 52
HSIC Henry Schein, Inc. $86.84 +0.25% 10B 71
ATR AptarGroup, Inc. $127.71 +1.35% $8.15B 75
NYXH Nyxoah S.A. $1.62 -8.47% $64.16M 69
KMTS Kestra Medical Technologies, Ltd. $28.08 +0.73% $1.64B 67
ZTEK Zentek Ltd. $0.51 +10.73% $55.26M 63

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AVTR's Key Strengths?

  • Diversified product and service portfolio.
  • Global presence and established distribution network.
  • Strong relationships with key customers in diverse industries.
  • Expertise in providing mission-critical products and services.

What Are AVTR's Weaknesses?

  • Negative profit margin.
  • Exposure to economic cycles and fluctuations in demand.
  • Dependence on key suppliers for certain materials and components.
  • Potential for product liability claims.

What Could Drive AVTR Stock Higher?

  • Expansion of service offerings in the biopharma sector to drive revenue growth.
  • Penetration of emerging markets in Asia and Africa to diversify revenue streams.
  • Potential strategic acquisitions to expand product portfolio and geographic reach.
  • Increasing adoption of single-use technologies in biopharmaceutical manufacturing.
  • Enhancement of digital capabilities to improve customer experience and operational efficiency.

What Are the Key Risks for AVTR?

  • Financial-distress signal — its Altman Z-Score of 1.49 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-9.6%) — the business is not currently generating profit on shareholder capital.
  • Intense competition from established players in the medical instruments and supplies industry.
  • Stringent regulatory requirements and compliance costs impacting profitability.
  • Disruptions in the supply chain affecting the availability of key materials and components.
  • Technological advancements rendering existing products obsolete.
  • Fluctuations in demand from key customer segments due to economic cycles.

What Are the Growth Opportunities for AVTR?

  • Expansion of Biopharma Services: Avantor can capitalize on the growing biopharmaceutical market by expanding its service offerings, including biopharmaceutical material scale-up and development services. The global biopharmaceutical market is expected to reach $526 billion by 2028, presenting a significant opportunity for Avantor to increase its market share through specialized services and customized solutions. This expansion can be achieved through strategic partnerships and investments in advanced technologies.
  • Penetration of Emerging Markets: Entering and expanding in emerging markets, particularly in Asia and Africa, offers substantial growth potential. These regions are experiencing rapid growth in healthcare spending and industrial development, creating a demand for Avantor's products and services. By establishing a stronger presence in these markets, Avantor can diversify its revenue streams and reduce its reliance on mature markets. This strategy involves building local partnerships and tailoring product offerings to meet regional needs.
  • Strategic Acquisitions: Avantor can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate Avantor's growth and enhance its competitive position. For example, acquiring a company specializing in advanced filtration systems could strengthen Avantor's equipment and instrumentation offerings. These acquisitions should be carefully evaluated to ensure they align with Avantor's overall strategy and create synergies.
  • Focus on Single-Use Technologies: The increasing adoption of single-use technologies in biopharmaceutical manufacturing presents a significant growth opportunity for Avantor. Single-use systems offer advantages such as reduced cleaning requirements, lower capital investment, and faster changeover times. By investing in the development and manufacturing of customized single-use assemblies, Avantor can cater to the growing demand for these technologies and strengthen its relationships with biopharmaceutical customers. This includes expanding its offerings of single-use bioreactors, mixers, and fluid transfer systems.
  • Enhancement of Digital Capabilities: Investing in digital technologies to improve customer experience and operational efficiency is crucial for sustained growth. This includes developing e-commerce platforms, implementing advanced data analytics, and leveraging artificial intelligence to optimize supply chain management. By enhancing its digital capabilities, Avantor can improve customer satisfaction, reduce costs, and gain a competitive edge in the market. This also involves providing customers with online tools for product selection, ordering, and technical support.

What Opportunities Does AVTR Have?

  • Expansion of biopharma services.
  • Penetration of emerging markets.
  • Strategic acquisitions to expand product portfolio.
  • Increasing adoption of single-use technologies.

What Threats Does AVTR Face?

  • Intense competition from established players.
  • Stringent regulatory requirements and compliance costs.
  • Potential disruptions in supply chain.
  • Technological advancements rendering existing products obsolete.

What Are AVTR's Competitive Advantages?

  • Diversified product and service portfolio reduces reliance on any single product or market.
  • Strong relationships with key customers in diverse industries provide recurring revenue.
  • Global presence allows for economies of scale and access to multiple markets.
  • Specialized expertise in providing mission-critical products and services creates a barrier to entry.
  • Long-standing history and established reputation build trust and customer loyalty.

What Does AVTR Do?

Founded in 1904 and headquartered in Radnor, Pennsylvania, Avantor, Inc. has evolved into a global provider of mission-critical products and services. The company serves a wide array of industries, including biopharma, healthcare, education and government, advanced technologies, and applied materials. Avantor's offerings span materials and consumables, such as high-purity chemicals, reagents, lab supplies, formulated silicone materials, customized excipients, and single-use assemblies. They also provide process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. In addition to materials, Avantor supplies equipment and instrumentation, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and peristaltic pumps. The company further extends its capabilities through services and specialty procurements, offering onsite lab and production support, equipment services, procurement and sourcing solutions, and biopharmaceutical material scale-up and development services. Avantor also provides scientific research support services, including DNA extraction, bioreactor servicing, clinical and biorepository services, compound management, cleanroom control, monitoring, maintenance, and sanitization services. Avantor’s global presence allows it to serve customers across the Americas, Europe, Asia, the Middle East, and Africa, making it a key player in supporting scientific advancements and industrial processes worldwide. With a workforce of 13,500 employees, Avantor continues to innovate and expand its offerings to meet the evolving needs of its diverse customer base.

What Products and Services Does AVTR Offer?

  • Provides materials and consumables like high-purity chemicals and reagents.
  • Offers lab products and supplies, including customized excipients and single-use assemblies.
  • Supplies equipment and instrumentation, such as filtration systems and incubators.
  • Delivers services and specialty procurements, including onsite lab and production support.
  • Provides scientific research support services like DNA extraction and bioreactor servicing.
  • Serves the biopharma, healthcare, education, government, advanced technologies, and applied materials industries.
  • Offers clinical trial kits and fluid handling tips.

How Does AVTR Make Money?

  • Sells materials and consumables to research and production facilities.
  • Provides equipment and instrumentation for laboratories and manufacturing processes.
  • Offers services and specialty procurements, generating revenue through service contracts.
  • Serves diverse industries, creating multiple revenue streams.
  • Focuses on long-term relationships with customers, ensuring recurring revenue.

What Industry Does AVTR Operate In?

Avantor, Inc. operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced healthcare solutions. The global medical devices market is projected to reach $600 billion by 2028, driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. Avantor competes with companies like Baxter International Inc. and Henry Schein, Inc., focusing on providing specialized products and services to maintain a competitive edge. The industry is also influenced by stringent regulatory requirements and the need for continuous product development to meet evolving customer needs.

Who Are AVTR's Key Customers?

  • Biopharmaceutical companies conducting research and manufacturing.
  • Healthcare providers and research institutions.
  • Educational and governmental organizations.
  • Advanced technology companies requiring specialized materials.
  • Applied materials industries needing high-purity chemicals and equipment.
AI Confidence: 73% Updated: May 4, 2026

FY2026 estForward Outlook

Wall Street analysts project Avantor, Inc. revenue of about $6.50B for fiscal 2026, with EPS near $0.79. The estimate reflects 12 contributing analysts.

Quarterly Financial Performance: Avantor, Inc.

Revenue for Avantor, Inc. came in at $1.58B during Q1 2026, a 4.9% contraction versus the preceding quarter. The company recorded net income of $43.3M, with diluted EPS of $0.06. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, AVTR averaged $-0.20 in diluted EPS.

AVTR Valuation & Market Position

With a $6.96B market cap, Avantor, Inc. sits in the mid-cap segment of the market. Relative to its peer group, AVTR's quantitative score of 48/100 is below the peer average of 67/100.

ROE -10%Key Financial Metrics

Return on equity for Avantor, Inc. stands at -9.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Avantor, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.49 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Avantor, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Radnor, US. The company is led by CEO Emmanuel Ligner. AVTR has traded publicly since 2019.

AVTR Financials

Fundamental Snapshot

Revenue Growth (FY)
-3.4%
Net Income Growth (FY)
-174.5%
EPS Growth (FY)
-174.3%
Free Cash Flow Growth (FY)
-28.5%
Return on Equity (TTM)
-9.6%
Current Ratio
1.8
EV/EBITDA (TTM)
48.6

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying signals confidence in Avantor's growth potential, suggesting that key executives believe in the company's future.
  • Community sentiment has turned increasingly positive, with discussions highlighting Avantor's strong position in the life sciences sector.
  • The recent expansion of Avantor's product offerings is being well-received, indicating a strategic move to capture more market share.
  • Investors are optimistic about the company's partnerships and collaborations, which are seen as catalysts for future growth.

Bear Case

  • Concerns about supply chain disruptions have surfaced, raising questions about Avantor's ability to meet demand effectively.
  • Some community members express skepticism regarding the company's valuation, arguing that it may not reflect its current performance.
  • Recent earnings reports have shown mixed results, leading to debates about the sustainability of Avantor's growth trajectory.
  • Market perception has been cautious, with chatter about potential regulatory challenges that could impact Avantor's operations.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q1 2026 $1.58B $43M $0.06
Q4 2025 $1.66B $52M $0.08
Q3 2025 $1.62B -$712M -$1.04
Q2 2025 $1.68B $65M $0.09

Based on FMP financials and quantitative analysis

AVTR Latest News

AVTR Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVTR.

Price Targets

Consensus target: $10.89

AVTR MoonshotScore

48/100

What does this score mean?

The MoonshotScore rates AVTR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Latest Avantor, Inc. Analysis

Avantor, Inc. Healthcare Stock: Key Questions Answered

What does Avantor, Inc. do?

Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries. The company offers a comprehensive range of materials and consumables, equipment and instrumentation, and services and specialty procurements. These offerings support research, development, and production activities across various sectors, enabling Avantor to serve as a key partner for scientific and industrial advancements worldwide. Its global presence allows it to cater to diverse customer needs and maintain a competitive edge.

What do analysts say about AVTR stock?

Analyst consensus on Avantor, Inc. reflects a mixed outlook, with some highlighting the company's diversified revenue streams and exposure to high-growth sectors as positive factors. Key valuation metrics, such as price-to-earnings ratio and enterprise value-to-EBITDA, are closely monitored to assess the company's relative valuation. Growth considerations include the company's ability to expand its service offerings, penetrate emerging markets, and execute strategic acquisitions. However, analysts also note risks such as intense competition and potential fluctuations in demand from key customer segments.

What are the main risks for AVTR?

Avantor, Inc. faces several key risks, including intense competition from established players in the medical instruments and supplies industry, which could pressure pricing and market share. Stringent regulatory requirements and compliance costs pose ongoing challenges to profitability. Potential disruptions in the supply chain could affect the availability of key materials and components, impacting production and customer satisfaction. Additionally, technological advancements could render existing products obsolete, requiring continuous innovation and investment in research and development. Fluctuations in demand from key customer segments due to economic cycles also represent a significant risk.

What are the key factors to evaluate for AVTR?

Avantor, Inc. (AVTR) holds an AI score of 48/100 (low). P/E: 9.2x vs the S&P 500's ~20-25x. Analysts target $10.89 (+7%). Not financial advice.

How frequently does AVTR data refresh on this page?

AVTR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven AVTR's recent stock price performance?

Avantor, Inc. (AVTR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product and service portfolio. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AVTR overvalued or undervalued right now?

Avantor, Inc. (AVTR) trades at 9.2x earnings. Analysts target $10.89 (+7%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying AVTR?

Before investing in Avantor, Inc. (AVTR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
Data Sources

Popular Stocks